Daratumumab, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Meta‐Analysis

Documenti analoghi

• Comparison of Time to Next Treatment or Death Between Front‐Line Daratumumab, Lenalidomide, and Dexamethasone ( DRd ) Versus Bortezomib, Lenalidomide, and Dexamethasone ( VRd ) Among Transplant‐Ineligible Patients With Multiple Myeloma
  di: Doris K. Hansen, et al.
  Pubblicazione: (2024)
• Sustained Improvement in Health‐Related Quality of Life in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient‐Reported Outcomes
  di: Aurore Perrot, et al.
  Pubblicazione: (2025)
• Real‐World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated With Front‐Line Daratumumab Lenalidomide and Dexamethasone
  di: Ricardo D. Parrondo, et al.
  Pubblicazione: (2026)
• Balancing the Risk of Cardiotoxicity Outcomes in Treatment Selection for Multiple Myeloma: A Retrospective Multicenter Evaluation of Ixazomib, Lenalidomide, and Dexamethasone (IRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (KRd)
  di: Benjamin J. Lee, et al.
  Pubblicazione: (2025)
• Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial
  di: Paul Richardson, et al.
  Pubblicazione: (2025)